Your browser doesn't support javascript.
loading
Safety of Cohesive Polydensified Matrix Cross-Linked Hyaluronic Acid Volumizing Gel in Temporal Hollows and Cheeks: A Prospective, Open-Label, Postmarket Study.
Pavicic, Tatjana; Sattler, Gerhard; Prager, Welf; Fischer, Tanja; Gauglitz, Gerd; Hofmann, Matthias; Dersch, Hanna; Riaz, Shahbaz; Kerscher, Martina.
Afiliación
  • Pavicic T; Privatpraxis für Dermatologie und Ästhetik Maximilianstr, Munich, Germany.
  • Sattler G; Rosenparkklinik GmbH, Darmstadt, Germany.
  • Prager W; Prager & Partner Dermatologische Praxis, Hamburg, Germany.
  • Fischer T; Haut-und Lasercentrum Berlin-Potsdam, Praxis Potsdam, Potsdam, Germany.
  • Gauglitz G; Dermatologie München-Neuhausen, Leonrodstraße, Munich, Germany.
  • Hofmann M; Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
  • Dersch H; Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
  • Riaz S; Merz North America, Inc., Raleigh, North Carolina.
  • Kerscher M; Division of Biochemistry and Molecular Biology, Cosmetic Science, University of Hamburg, Hamburg, Germany.
Dermatol Surg ; 47(10): 1359-1364, 2021 10 01.
Article en En | MEDLINE | ID: mdl-34417392
ABSTRACT

BACKGROUND:

Facial aging is characterized by volume loss and progressive hollowing of temples and cheeks. Biodegradable filler materials are preferred over nonabsorbable materials; of these, hyaluronic acid (HA) fillers are the most often used because of their favorable effectiveness and safety profile.

OBJECTIVE:

To confirm the safety and effectiveness of Cohesive Polydensified Matrix (CPM)-HA26 gel in the treatment of volume deficiency.

METHODS:

Subjects received up to 2 treatments in the temples and/or cheeks. A blinded investigator assessed improvement according to the Merz Temple Volume Scale (MTVS) and Merz Cheek Fullness Assessment Scale (MCFAS). Subjects were followed for 48 weeks after the last treatment.

RESULTS:

In total, 87 healthy subjects were enrolled. The proportion of subjects achieving at least a 1-grade improvement on MTVS and/or MCFAS was above 70% for each (MTVS Weeks 4, 24, and 48 = 95.4%, 94.2%, and 77.0%; MCFAS Weeks 4, 24, and 48 = 92.3%, 83.1%, and 71.8%). Based on MTVS and MCFAS scores at Visit 5, improvement remained visible at up to 48 weeks. No treatment-related serious AEs occurred.

CONCLUSION:

CPM-HA26 demonstrated both a favorable safety and effectiveness profile, with improvement in facial volume evident for up to 48 weeks. It was well tolerated and had a positive, long-lasting effect.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Técnicas Cosméticas / Rellenos Dérmicos / Ácido Hialurónico Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Dermatol Surg Asunto de la revista: DERMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Técnicas Cosméticas / Rellenos Dérmicos / Ácido Hialurónico Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Dermatol Surg Asunto de la revista: DERMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Alemania